Zydus receives final approval from USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets).

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders. The product will be manufactured at the group's formulation manufacturing facility at Baddi, Himachal Pradesh.

Dexamethasone Tablets USP, 1 mg had annual sales of USD 1.8 mn in the United States (IQVIA MAT March 24).

The group now has 395 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1005.75 as compared to the previous close of Rs. 980.65. The total number of shares traded during the day was 25877 in over 1741 trades.

The stock hit an intraday high of Rs. 1007.30 and intraday low of 972.85. The net turnover during the day was Rs. 25679376.00.

(*as of 31st December 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA Approval DexamethasoneTablets